Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness

Peng Meng, Roble G. Bedolla, Huiyoung Yun, James E. Fitzpatrick, Addanki P Kumar, Rita Ghosh

Research output: Contribution to journalArticle

Abstract

The general transcription factor E2F1 reportedly functions in a protumorigenic manner in several cancer models. We show that the genetic context of cancer cells influence E2F1's role to impede the protumorigenic role. Thirty to fifty percent of melanoma patients carry mutant BRAF with about 90% of mutant BRAF melanomas being V600E mutation. Tissue microarrays from melanoma patients were used to establish an association between E2F1 and BRAFV600E. We show for the first time that low E2F1 levels in BRAFV600E melanomas are associated with lymph node metastasis. Genetic manipulation of E2F1 in BRAFV600E and BRAFwt cells were used to determine its role in malignant melanoma progression by examining effects on migration and invasion. E2F1-mediated negative regulation of myosin light chain kinase (MYLK) increased migration and invasion in BRAFV600E cells by phosphorylating myosin light chain and increased stress fiber formation. We show that E2F1 inhibits extracellular signal-regulated kinase (ERK) activation in BRAFV600E cells and provide evidence for a negative feedback loop between E2F1 and ERK in these cells. This study shows for the first time that E2F1 has a cancer protective role in oncogenic BRAF-activated melanoma cells and that loss of E2F1 can allow disease progression through a novel mechanism of E2F1-mediated MYLK regulation. This study has implications for oncogenic BRAF-activated tumors and resistance to targeted oncogenic BRAF therapy.

Original languageEnglish (US)
Pages (from-to)1701-1710
Number of pages10
JournalMolecular Carcinogenesis
Volume58
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cell Movement
Melanoma
Myosin-Light-Chain Kinase
Extracellular Signal-Regulated MAP Kinases
Neoplasms
General Transcription Factors
Stress Fibers
Myosin Light Chains
Disease Progression
Lymph Nodes
Neoplasm Metastasis
Mutation

Keywords

  • cytoskeleton
  • E2F1
  • infiltration
  • malignant melanoma
  • mutant BRAF
  • myosin light chain kinase

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness. / Meng, Peng; Bedolla, Roble G.; Yun, Huiyoung; Fitzpatrick, James E.; Kumar, Addanki P; Ghosh, Rita.

In: Molecular Carcinogenesis, Vol. 58, No. 9, 01.01.2019, p. 1701-1710.

Research output: Contribution to journalArticle

Meng, Peng ; Bedolla, Roble G. ; Yun, Huiyoung ; Fitzpatrick, James E. ; Kumar, Addanki P ; Ghosh, Rita. / Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness. In: Molecular Carcinogenesis. 2019 ; Vol. 58, No. 9. pp. 1701-1710.
@article{f72d996410174dd6adfea7616d65d49f,
title = "Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness",
abstract = "The general transcription factor E2F1 reportedly functions in a protumorigenic manner in several cancer models. We show that the genetic context of cancer cells influence E2F1's role to impede the protumorigenic role. Thirty to fifty percent of melanoma patients carry mutant BRAF with about 90{\%} of mutant BRAF melanomas being V600E mutation. Tissue microarrays from melanoma patients were used to establish an association between E2F1 and BRAFV600E. We show for the first time that low E2F1 levels in BRAFV600E melanomas are associated with lymph node metastasis. Genetic manipulation of E2F1 in BRAFV600E and BRAFwt cells were used to determine its role in malignant melanoma progression by examining effects on migration and invasion. E2F1-mediated negative regulation of myosin light chain kinase (MYLK) increased migration and invasion in BRAFV600E cells by phosphorylating myosin light chain and increased stress fiber formation. We show that E2F1 inhibits extracellular signal-regulated kinase (ERK) activation in BRAFV600E cells and provide evidence for a negative feedback loop between E2F1 and ERK in these cells. This study shows for the first time that E2F1 has a cancer protective role in oncogenic BRAF-activated melanoma cells and that loss of E2F1 can allow disease progression through a novel mechanism of E2F1-mediated MYLK regulation. This study has implications for oncogenic BRAF-activated tumors and resistance to targeted oncogenic BRAF therapy.",
keywords = "cytoskeleton, E2F1, infiltration, malignant melanoma, mutant BRAF, myosin light chain kinase",
author = "Peng Meng and Bedolla, {Roble G.} and Huiyoung Yun and Fitzpatrick, {James E.} and Kumar, {Addanki P} and Rita Ghosh",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mc.23043",
language = "English (US)",
volume = "58",
pages = "1701--1710",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness

AU - Meng, Peng

AU - Bedolla, Roble G.

AU - Yun, Huiyoung

AU - Fitzpatrick, James E.

AU - Kumar, Addanki P

AU - Ghosh, Rita

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The general transcription factor E2F1 reportedly functions in a protumorigenic manner in several cancer models. We show that the genetic context of cancer cells influence E2F1's role to impede the protumorigenic role. Thirty to fifty percent of melanoma patients carry mutant BRAF with about 90% of mutant BRAF melanomas being V600E mutation. Tissue microarrays from melanoma patients were used to establish an association between E2F1 and BRAFV600E. We show for the first time that low E2F1 levels in BRAFV600E melanomas are associated with lymph node metastasis. Genetic manipulation of E2F1 in BRAFV600E and BRAFwt cells were used to determine its role in malignant melanoma progression by examining effects on migration and invasion. E2F1-mediated negative regulation of myosin light chain kinase (MYLK) increased migration and invasion in BRAFV600E cells by phosphorylating myosin light chain and increased stress fiber formation. We show that E2F1 inhibits extracellular signal-regulated kinase (ERK) activation in BRAFV600E cells and provide evidence for a negative feedback loop between E2F1 and ERK in these cells. This study shows for the first time that E2F1 has a cancer protective role in oncogenic BRAF-activated melanoma cells and that loss of E2F1 can allow disease progression through a novel mechanism of E2F1-mediated MYLK regulation. This study has implications for oncogenic BRAF-activated tumors and resistance to targeted oncogenic BRAF therapy.

AB - The general transcription factor E2F1 reportedly functions in a protumorigenic manner in several cancer models. We show that the genetic context of cancer cells influence E2F1's role to impede the protumorigenic role. Thirty to fifty percent of melanoma patients carry mutant BRAF with about 90% of mutant BRAF melanomas being V600E mutation. Tissue microarrays from melanoma patients were used to establish an association between E2F1 and BRAFV600E. We show for the first time that low E2F1 levels in BRAFV600E melanomas are associated with lymph node metastasis. Genetic manipulation of E2F1 in BRAFV600E and BRAFwt cells were used to determine its role in malignant melanoma progression by examining effects on migration and invasion. E2F1-mediated negative regulation of myosin light chain kinase (MYLK) increased migration and invasion in BRAFV600E cells by phosphorylating myosin light chain and increased stress fiber formation. We show that E2F1 inhibits extracellular signal-regulated kinase (ERK) activation in BRAFV600E cells and provide evidence for a negative feedback loop between E2F1 and ERK in these cells. This study shows for the first time that E2F1 has a cancer protective role in oncogenic BRAF-activated melanoma cells and that loss of E2F1 can allow disease progression through a novel mechanism of E2F1-mediated MYLK regulation. This study has implications for oncogenic BRAF-activated tumors and resistance to targeted oncogenic BRAF therapy.

KW - cytoskeleton

KW - E2F1

KW - infiltration

KW - malignant melanoma

KW - mutant BRAF

KW - myosin light chain kinase

UR - http://www.scopus.com/inward/record.url?scp=85070653946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070653946&partnerID=8YFLogxK

U2 - 10.1002/mc.23043

DO - 10.1002/mc.23043

M3 - Article

C2 - 31124185

AN - SCOPUS:85070653946

VL - 58

SP - 1701

EP - 1710

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 9

ER -